EMEA-001119-PIP02-12-M04

Key facts

Invented name
  • Lenvima
  • Kisplyx
Active substance
Lenvatinib
Therapeutic area
Oncology
Decision number
P/0389/2018
PIP number
EMEA-001119-PIP02-12-M04
Pharmaceutical form(s)
Capsule hard
Condition(s) / indication(s)
  • Treatment of follicular thyroid cancer
  • Treatment of osteosarcoma
  • Treatment of papillary thyroid cancer
Route(s) of administration
Oral use
Contact for public enquiries
Eisai Europe Ltd

E-mail: eumedinfo@eisai.net
Tel. +44 (0)8456 761400

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating